Dear Dr Chadwick

Medicines Australia Code of Conduct

Cancer Voices Australia writes to ask the ACCC not to approve the Medicine’s Australia Code of Conduct. We were invited to, and attended, several consumer forums organised by Medicines Australia regarding their proposed changes and we remain highly disappointed that the proposed amendments to the transparency provisions of the Code of Conduct will not at all provide cancer patients and their families with transparency around sponsorship and fees paid to health care practitioners (“practitioners”).

We consider what has been proposed is totally insufficient. It needs to be recognised that, in our society, gifts are seen, and usually designed, to influence people. Relying on a practitioner to consent will defeat the purpose of the changes to the Code. There is no incentive for a practitioner to consent. While Medicines Australia say they will monitor the number of practitioners who consent, this will just mean a further delay while we see if this “model” works before further changes are made which have some remote chance of giving patients information which really they should be entitled to know now.

As a number of people advocated at the forums we attended, including Cancer Voices, there is a simple way to achieve what Medicines Australia say they want using the same model they have developed – members of Medicines Australia agree they will not provide sponsorship or gifts to a practitioner unless consent is given to publicly disclose the information. While it is true that consent may later be withdrawn by a practitioner, we strongly believe that if Medicines Australia and the ACCC are serious about providing such information to patients, the starting/default position must be disclosure.

We also consider the proposed delay in provision of information to be so great as to render the information essentially useless to patients. We understand of course there would need to be an initial period to allow practitioners and companies to set up the necessary systems to ensure disclosure was accurate. We are not unreasonable. However beyond the initial set up, it should be possible to provide timely information to the public. The current proposal sees delays of up to 10 months between receipt of the gift by a practitioner and notification. This is not acceptable and frankly such a delay means the information will be of limited, if any at all, use to patients. We draw your attention to, for example, the Parliamentary Register of Pecuniary Interests which requires Members and Senators to disclose gifts etc within 28 days of receipt. If some of the gifts
and benefits received by the medical profession were routinely received by our politicians, the community would be rightly outraged. The MA proposals are a waste of time.

We are also concerned about the method of disclosure. From a patient’s perspective, we will need to search each company individually to see (10 months later) any activity relating to our practitioner (assuming they have provided consent). We strongly recommend a central database be developed as a priority – one which can be searched by both drug and practitioner name. Until that can be developed, at the very least companies should have reports which can be similarly searched. It is also important that the information remains available for longer than the two years MA has proposed. We think five years is a period which provides a sufficient balance between the patient’s right to know and the administrative burden on the company.

We are also concerned that the proposal relates to sponsorship or gifts given to individual practitioners only and not, for example, sponsorship or gifts given to a small practice. This remains an obvious way around the proposed regime.

We are incredibly disappointed with the proposal as it currently stands and do not think such tokenism advances transparency for patients at all. The upshot of the current proposal is that, from a patient’s perspective, we will be able to see that our doctor has directly received (ie not through their practice etc) a benefit from a pharmaceutical company regarding the new drug she/he put us on, if our doctor consents to it being made public, about 12 months later. Such limited information, provided after such a delay, is hardly worth the effort and expense of bringing in a new system.

We hope the ACCC does not endorse the Code in this form. To do so would only give it a cloak of respectability and, frankly, also diminish the reputation of the ACCC.

Yours sincerely

Sally Crossing AM
Executive Committee

1 August 2014